6th Jun 2007 07:42
AstraZeneca PLC06 June 2007 (NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO ORFROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULDCONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION) AstraZeneca Successfully Completes Tender Offer for MedImmune Shares AstraZeneca PLC ("AstraZeneca") today announced that it successfully completedits tender offer for all of the outstanding shares of common stock of MedImmune,Inc. ("MedImmune"). The subsequent offering period for the offer expired at 12:00 midnight, New York City time, on Tuesday, June 5, 2007. AstraZenecaBiopharmaceuticals Inc., a wholly owned subsidiary of AstraZeneca, purchased inthe initial and subsequent offering periods of the offer a total ofapproximately 218,750,474 MedImmune shares (excluding shares tendered throughnotices of guaranteed delivery which have not to date been received),representing approximately 91.6% of the outstanding shares of MedImmune. As previously announced, AstraZeneca expects to effect, without a vote ormeeting of MedImmune's stockholders, a short-form merger on or about June 18,2007 to complete the MedImmune acquisition. Following the merger, MedImmunewill be an indirect wholly owned subsidiary of AstraZeneca. In the merger, eachof the remaining shares of MedImmune common stock (other than any shares inrespect of which appraisal rights are validly exercised under Delaware law andany shares owned by MedImmune, AstraZeneca or any of their subsidiaries) will beconverted into the right to receive the same $58.00 in cash per share, withoutinterest, that was paid in the tender offer. Following the merger, MedImmune'scommon stock will cease to be traded on the NASDAQ Global Select Market. -Ends- June 6th 2007 AstraZenecaMedia Enquiries:Steve Brown / Edel McCaffrey (London) (020) 7304 5033/5034Staffan Ternby (Sweden) (8) 553 26107Emily Denney (Wilmington) (302) 885 3451Analyst/Investor Enquiries:Jonathan Hunt / Mina Blair / Karl Hard (London) (020) 7304 5087/5084/5322Staffan Ternby (Sweden) (8) 553 26107Ed Seage / Jorgen Winroth (US) (302) 886 4065/(212) 579 0506Merrill Lynch (Financial Adviser to AstraZeneca) +44 (0) 20 7628 1000Richard GirlingDeutsche Bank (Joint Corporate Broker to AstraZeneca) +44 (0) 20 7545 8000Charlie ForemanGoldman Sachs (Joint Corporate Broker to AstraZeneca) +44 (0) 20 7774 1000Phil Raper MedImmune Media Enquiries:Jamie Lacey 301-398-4035Analyst/Investor Enquiries:Pete Vozzo 301-398-4358 Not for release, publication or distribution, in whole or in part, in, into orfrom Australia, Canada or Japan This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca